DARE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
187.5K
+23.0%
152.5K
-85.1%
1.0M
+45155.3%
2.3K
+110.7%
-21172
Cost of Revenue
319.9K
+32.0%
242.3K
-18.1%
295.8K
0
0
Gross Profit
-132343
-47.3%
-89870
-112.3%
727.9K
+32078.5%
2.3K
+110.7%
-21172
Operating Expenses
2.8M
-2.5%
2.9M
+32.3%
2.2M
-40.1%
3.7M
-3.5%
3.8M
R&D
242.0K
-63.4%
660.5K
+6.2%
622.0K
-47.1%
1.2M
-17.7%
1.4M
SG&A
2.6M
+15.3%
2.2M
+42.6%
1.6M
-36.9%
2.5M
+5.1%
2.4M
Operating Income
-2967980
+1.0%
-2998898
-103.8%
-1471268
+59.9%
-3672148
+4.1%
-3827800
EBITDA
-2395837
+2.0%
-2444255
-160.9%
-936873
+70.6%
-3190242
+5.4%
-3373635
Net Income
-2982773
+0.6%
-2999889
-108.1%
-1441718
+59.5%
-3562766
+11.3%
-4016483
EPS (Basic)
$-0.20
+4.8%
$-0.21
-110.0%
$-0.10
+64.3%
$-0.28
+37.8%
$-0.45
EPS (Diluted)
$-0.20
+4.8%
$-0.21
-110.0%
$-0.10
+64.3%
$-0.28
+37.8%
$-0.45
Shares (Diluted)
14.9M
+2.5%
14.5M
+1.3%
14.3M
+12.3%
12.8M
+43.8%
8.9M
Dare Bioscience (DARE) โ€” Financials